Oxurion NV: Oxurion Provides Update on Clinical Pipeline Pro

Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME) in treatment naïve subjects US IRB Approval of Protocol Amendment

Related Keywords

Boston , Massachusetts , United States , Nevada , Leuven , Region Flamande , Belgium , Reno , Tom Graney , Michael Dillen , Arshadm Khanani , Sylvie Berrebi Frazer Hall , Christopher Brinzey , Company Annual , Clinical Research At Sierra Eye Associates , Completed Patient Enrollment , Diabetic Macular Edema , Protocol Amendment , Euronext Brussels , Patient Enrollment , Age Related Macular Degeneration , Retinal Vein Occlusion , Chief Executive Officer , Review Board , Best Corrected Vision , Clinical Research , Sierra Eye Associates , Oxurion , Rovides , Update , Linical , Pipeline , Progress ,